Moreover, we hope that our research findings to lead to the development of treatments targeting the hCCL18–CCR8 pathway as a rescue therapy for intractable IgG4-RD cases such as steroid-resistant cases and recurrent cases. Here, CCR8 is linked to immunoglobulin G4-related sclerosing disease.